GLP-1 receptor agonist diabetes medications linked to reduced dementia risk

[avo1122]

The research analyzed data from 26 randomized controlled trials with a total of 164,531 participants. While glucose-lowering therapies as a whole did not significantly reduce dementia risk, GLP-1 receptor agonists (GLP-1Ras) were linked to a 45% lower risk of dementia. The findings provide crucial insights into the potential for diabetes medications to influence long-term brain health.

https://jamanetwork.com/journals/jamaneurology/fullarticle/2831975